MHRA allows HAE patients early access to berotralstat
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Read More
Tag: berotralstat
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
